ADHD:
Indications for: EVEKEO
Attention deficit hyperactivity disorder.
Adults and Children:
<3yrs: not recommended. Avoid late evening doses; give first dose upon awakening and additional doses at 4–6hr intervals. Individualize. 3–5yrs: initially 2.5mg daily, may increase by 2.5mg/day at weekly intervals. ≥6yrs: initially 5mg once or twice daily; may increase by 5mg/day at weekly intervals; max 40mg/day.
EVEKEO Contraindications:
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate-to-severe hypertension. Hyperthyroidism. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Boxed Warning:
Amphetamines have a high potential for abuse; administration for long periods of time may lead to dependence and must be avoided.
Misuse may cause sudden death and serious cardiovascular adverse events.
EVEKEO Warnings/Precautions:
Abuse potential (monitor). Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder. Depression. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Evaluate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reevaluate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
EVEKEO Classification:
CNS stimulant.
EVEKEO Interactions:
See Contraindications. Avoid concomitant antacids. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide, some thiazides), propoxyphene. Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May antagonize effects of adrenergic blockers, antihistamines, veratrum alkaloids, antihypertensives. May potentiate effects of tricyclic antidepressants, meperidine, norepinephrine. May delay absorption of phenytoin, phenobarbital, ethosuximide. Monitor effects when concomitant PPIs. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid tests.
Adverse Reactions:
Palpitations, tachycardia, BP increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido change, prolonged erection, rhabdomyolysis; serious cardiovascular events, visual disturbances.
Drug Elimination:
Renal.
Generic Drug Availability:
NO
How Supplied:
Tabs—100
Obesity:
Indications for: EVEKEO
Short-term adjunct in managing exogenous obesity.
Clinical Trials:
Adult obese patients instructed in dietary management and treated with anorectic drugs lose more weight on average than those receiving placebo and diet, as determined in relatively short-term clinical trials.
The magnitude of increased weight loss of drug-treated patients over placebo patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo patients and tends to decrease in succeeding weeks.
The total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.
Adult Dosage:
Take 30–60 mins before meals. Usually up to 30mg/day in divided doses of 5–10mg.
Children Dosage:
Not recommended.
EVEKEO Contraindications:
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate-to-severe hypertension. Hyperthyroidism. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Boxed Warning:
Amphetamines have a high potential for abuse; administration for long periods of time may lead to dependence and must be avoided.
Misuse may cause sudden death and serious cardiovascular adverse events.
EVEKEO Warnings/Precautions:
Abuse potential (monitor). Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder. Depression. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Evaluate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reevaluate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
EVEKEO Classification:
CNS stimulant.
EVEKEO Interactions:
See Contraindications. Avoid concomitant antacids. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide, some thiazides), propoxyphene. Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May antagonize effects of adrenergic blockers, antihistamines, veratrum alkaloids, antihypertensives. May potentiate effects of tricyclic antidepressants, meperidine, norepinephrine. May delay absorption of phenytoin, phenobarbital, ethosuximide. Monitor effects when concomitant PPIs. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid tests.
Adverse Reactions:
Palpitations, tachycardia, BP increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido change, prolonged erection, rhabdomyolysis; serious cardiovascular events, visual disturbances.
Drug Elimination:
Renal.
Generic Drug Availability:
NO
How Supplied:
Tabs—100
Sleep-wake disorders:
Indications for: EVEKEO
Narcolepsy.
Adults and Children:
Give first dose upon awakening and additional doses at 4–6hr intervals. Usual range 5–60mg/day. <6yrs: not recommended. 6–12yrs: initially 5mg daily, may increase by 5mg/day at weekly intervals. ≥12yrs: initially 10mg daily; may increase by 10mg/day at weekly intervals.
EVEKEO Contraindications:
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate-to-severe hypertension. Hyperthyroidism. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
Boxed Warning:
Amphetamines have a high potential for abuse; administration for long periods of time may lead to dependence and must be avoided.
Misuse may cause sudden death and serious cardiovascular adverse events.
EVEKEO Warnings/Precautions:
Abuse potential (monitor). Known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease: not recommended. Hypertension. Heart failure. Recent MI. Arrhythmias. Assess cardiovascular status. Psychosis. Bipolar disorder. Depression. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Evaluate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy including Raynaud's phenomenon; monitor for digital changes. Monitor HR, BP, growth in children. Reevaluate periodically. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
EVEKEO Classification:
CNS stimulant.
EVEKEO Interactions:
See Contraindications. Avoid concomitant antacids. Potentiated by alkalinizers (eg, sodium bicarbonate, acetazolamide, some thiazides), propoxyphene. Antagonized by acidifiers, chlorpromazine, haloperidol, lithium. May antagonize effects of adrenergic blockers, antihistamines, veratrum alkaloids, antihypertensives. May potentiate effects of tricyclic antidepressants, meperidine, norepinephrine. May delay absorption of phenytoin, phenobarbital, ethosuximide. Monitor effects when concomitant PPIs. Convulsions with propoxyphene overdose and amphetamines. May interfere with urinary steroid tests.
Adverse Reactions:
Palpitations, tachycardia, BP increase, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, motor/phonic tics, Tourette's syndrome, dry mouth, unpleasant taste, diarrhea, constipation, anorexia, weight loss, urticaria, impotence, libido change, prolonged erection, rhabdomyolysis; serious cardiovascular events, visual disturbances.
Drug Elimination:
Renal.
Generic Drug Availability:
NO
How Supplied:
Tabs—100
